💰 Financial Record

This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.